These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33318935)

  • 21. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
    Xing Q; Zhang ZW; Lin QH; Shen LH; Wang PM; Zhang S; Fan M; Zhu B
    Ann Transl Med; 2020 Mar; 8(5):250. PubMed ID: 32309397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
    Chen JH; Lee KY; Hu CJ; Chung CC
    Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy.
    Nishimura T; Ninomiya K; Nakashima M; Akagi S; Kuribayashi T; Higo H; Hotta K; Maeda Y; Ito H; Kiura K
    Intern Med; 2023 May; 62(9):1319-1322. PubMed ID: 36130891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
    Saishu Y; Yoshida T; Seino Y; Nomura T
    J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
    Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
    Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
    Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
    Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical Features of Myasthenia Gravis as an Immune-related Adverse Event].
    Suzuki S
    Brain Nerve; 2024 Jan; 76(1):27-32. PubMed ID: 38191136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
    Leaver PJ; Jang HS; Vernon ST; Fernando SL
    BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myasthenia Gravis Induced by Nivolumab: A Case Report.
    Mehta JJ; Maloney E; Srinivasan S; Seitz P; Cannon M
    Cureus; 2017 Sep; 9(9):e1702. PubMed ID: 29159009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
    Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
    Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab.
    Ueda K; Ogasawara N; Ito N; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Uemura K; Nishihara K; Nakiri M; Suekane S; Igawa T
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
    J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
    [No Abstract]   [Full Text] [Related]  

  • 38. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
    Möhn N; Beutel G; Gutzmer R; Ivanyi P; Satzger I; Skripuletz T
    J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31653079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis.
    Saito S; Hontsu S; Hiraoka J; Yamanaka A; Fujioka N; Shimada D; Okuda Y; Sugie K; Muro S
    Intern Med; 2024 Dec; 63(23):3209-3215. PubMed ID: 38658343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.